UB-612

BIOLOGICAL6 trials

Sponsors

United Biomedical Inc., Asia, Vaxxinity, Inc.

Conditions

COVID-19COVID-19 VaccinesCoronavirusCovid-19SARS-CoV-2

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

CompletedNCT04545749

United Biomedical Inc., AsiaCOVID-19

Start: 2020-09-25End: 2021-05-24Updated: 2022-08-26

A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

CompletedNCT04967742

United Biomedical Inc., AsiaCOVID-19

Start: 2021-08-05End: 2021-10-31Updated: 2022-08-26

A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.

WithdrawnNCT05167253

United Biomedical Inc., AsiaCOVID-19

Start: 2022-02-15End: 2022-10-31Updated: 2022-08-26

Phase 2

A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

WithdrawnNCT04683224

Vaxxinity, Inc.Coronavirus, Covid-19, SARS-CoV-2

Start: 2021-02-01End: 2023-03-22Updated: 2022-04-04

A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers

TerminatedNCT04773067

United Biomedical Inc., AsiaCOVID-19

Start: 2021-01-30End: 2022-03-08Updated: 2022-08-26

Phase 3

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Vaxxinity, Inc.COVID-19 Vaccines

Start: 2022-03-16End: 2023-09-30Updated: 2022-10-14

Related Papers

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

2025-07-211 citations

Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses

PLoS Pathogens2023-04-2036 citations

A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants

Journal of Clinical Investigation2022-03-2274 citations